<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Manag Care Spec Pharm</journal-id><journal-id journal-id-type="iso-abbrev">J Manag Care Spec Pharm</journal-id><journal-id journal-id-type="pmc-domain-id">4474</journal-id><journal-id journal-id-type="pmc-domain">jmcsp</journal-id><journal-id journal-id-type="publisher-id">jmcsp</journal-id><journal-title-group><journal-title>Journal of Managed Care &amp; Specialty Pharmacy</journal-title></journal-title-group><issn pub-type="ppub">2376-0540</issn><issn pub-type="epub">2376-1032</issn><publisher><publisher-name>Academy of Managed Care Pharmacy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10390943</article-id><article-id pub-id-type="pmcid-ver">PMC10390943.1</article-id><article-id pub-id-type="pmcaid">10390943</article-id><article-id pub-id-type="pmcaiid">10390943</article-id><article-id pub-id-type="pmid">32678719</article-id><article-id pub-id-type="doi">10.18553/jmcp.2020.20159</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Palli</surname><given-names initials="SR">Swetha R.</given-names></name><degrees>MS</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Frazer</surname><given-names initials="M">Monica</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>DuCharme</surname><given-names initials="M">Mary</given-names></name><degrees>MLIS</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Buikema</surname><given-names initials="AR">Ami R.</given-names></name><degrees>MPH</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Anderson</surname><given-names initials="AJ">Amy J.</given-names></name><degrees>MS</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Franchino-Elder</surname><given-names initials="J">Jessica</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><aff id="aff1"><label>1</label>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut.</aff><aff id="aff2"><label>2</label>Optum, Eden Prairie, Minnesota.</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>AUTHOR CORRESPONDENCE: Swetha R. Palli, MS, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., AOB 1C, Ridgefield, CT 06877. Tel.: 203.798.4460; Email: <email>swetha.palli@boehringer-ingelheim.com</email>.</corresp><fn fn-type="COI-statement"><p>This study was sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). Palli and Franchino-Elder are employees of BIPI. Frazer, DuCharme, Buikema, and Anderson are employees of Optum, which was contracted by BIPI to conduct this study. The authors received no direct compensation related to the development of the manuscript. BIPI was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations.</p></fn></author-notes><pub-date pub-type="ppub"><month>10</month><year>2020</year></pub-date><volume>26</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">442062</issue-id><elocation-id>10.18553/jmcp.2020.20159</elocation-id><pub-history><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>02</day><month>08</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-02 20:25:14.500"><day>02</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2020, Academy of Managed Care Pharmacy. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jmcp.2020.20159.pdf"/><abstract><sec><title>BACKGROUND:</title><p>The 2018 Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends combination long-acting muscarinic antagonists/long-acting beta2-agonists (LAMA + LABA) as preferred maintenance therapy for patients with symptomatic chronic obstructive lung disease (COPD) after monotherapy and stepping up to triple therapy (TT; LAMA + LABA + inhaled corticosteroids [ICS]) in case of further exacerbations. Restrictions on TT recommendations have primarily been driven by higher pneumonia risk associated with regular ICS use. Evidence suggests that TT is overprescribed, which may affect economic and clinical outcomes.</p></sec><sec><title>OBJECTIVE:</title><p>To compare health plan-paid costs, COPD exacerbations, and pneumonia diagnoses among patients newly treated with a LAMA + LABA regimen composed of tiotropium (TIO) + olodaterol (OLO) in a fixed-dose combination inhaler (TIO + OLO) or TT in a U.S. Medicare Advantage Part D insured population.</p></sec><sec><title>METHODS:</title><p>This retrospective study identified COPD patients aged &#8805; 40 years who were initiating TIO + OLO or TT (index regimen) between January 1, 2014, and March 31, 2018, from a national administrative claims database. Continuous insurance coverage for 12 months pretreatment (baseline) and &#8805; 30 days posttreatment (follow-up) was required. Patients were followed until the earliest of study end (May 31, 2018), discontinuation of index regimen (&#8805; 60-day gap in index regimen coverage), switch to a different regimen, or health plan disenrollment. Before analysis of outcomes, TIO + OLO and TT patients were 1:1 propensity score-matched on baseline demographics, comorbidities, COPD medication use, medical resource use, and costs. Cohort differences in post-match outcomes were assessed by Wald Z-test (annualized costs) and Kaplan-Meier method (time to first COPD exacerbation and pneumonia diagnosis).</p></sec><sec><title>RESULTS:</title><p>After matching, each cohort had 1,454 patients who were well balanced on baseline characteristics. Compared with TT, the TIO + OLO cohort incurred $7,041 (41.1%) lower mean COPD-related total costs ($10,094 vs. $17,135; <italic toggle="yes">P</italic> &lt; 0.001); cohort differences in the medical component ($3,666 lower for TIO + OLO) were driven by lower mean acute inpatient costs ($3,053 lower for TIO + OLO). Combined mean COPD plus pneumonia-related medical costs were $5,212 (39.0%) lower for TIO + OLO versus TT ($8,209 vs. $13,421; <italic toggle="yes">P</italic> = 0.006), and total mean all-cause costs were $9,221 (30.4%) lower for TIO + OLO versus TT ($21,062 vs. $30,283; <italic toggle="yes">P</italic> &lt; 0.001). Kaplan-Meier analysis found longer time to first severe COPD exacerbation (<italic toggle="yes">P</italic> = 0.020) and first pneumonia diagnosis (<italic toggle="yes">P</italic> = 0.002) for TIO + OLO versus TT and a lower percentage of TIO + OLO patients experiencing these events (severe COPD exacerbation: 9.0% vs. 16.1%; pneumonia: 14.5% vs. 19.3%). A secondary analysis, which expanded the TIO + OLO cohort to include any LAMA + LABA regimen, had similar findings for all outcomes.</p></sec><sec><title>CONCLUSIONS:</title><p>COPD patients initiating TIO + OLO incurred lower costs to health plans and experienced fewer COPD exacerbation and pneumonia events relative to TT. These findings provide important real-world economic and clinical insight into the GOLD recommendations for TIO + OLO and LAMA + LABA therapy. The study findings also indicate the continued inconsistency between the recommendations and real-world clinical practices pertaining to TT.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>